87 related articles for article (PubMed ID: 32233170)
1. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
Park J; Eoh KJ; Nam EJ; Kim S; Kim SW; Kim YT; Lee JY
Yonsei Med J; 2020 Apr; 61(4):284-290. PubMed ID: 32233170
[TBL] [Abstract][Full Text] [Related]
2. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
Coleman RL; Spirtos NM; Enserro D; Herzog TJ; Sabbatini P; Armstrong DK; Kim JW; Park SY; Kim BG; Nam JH; Fujiwara K; Walker JL; Casey AC; Alvarez Secord A; Rubin S; Chan JK; DiSilvestro P; Davidson SA; Cohn DE; Tewari KS; Basen-Engquist K; Huang HQ; Brady MF; Mannel RS
N Engl J Med; 2019 Nov; 381(20):1929-1939. PubMed ID: 31722153
[TBL] [Abstract][Full Text] [Related]
3. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".
van Wagensveld L; Colomban O; van der Aa MA; Freyer G; Sonke GS; Kruitwagen RFPM; You B
J Gynecol Oncol; 2024 May; 35(3):e34. PubMed ID: 38216134
[TBL] [Abstract][Full Text] [Related]
4. CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals.
Li C; Cui Q; Wang X; Yao S; Tu H; Chen M
BMC Cancer; 2024 May; 24(1):609. PubMed ID: 38769484
[TBL] [Abstract][Full Text] [Related]
5. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer.
Seol A; Kim SI; Yoon HY; Lee M; Kim HS; Chung HH; Park NH; Song YS
In Vivo; 2024; 38(3):1338-1350. PubMed ID: 38688599
[TBL] [Abstract][Full Text] [Related]
6. Association between BMI and oncologic outcomes in epithelial ovarian cancer: a predictors-matched case-control study.
Levin G; Brezinov Y; Tzur Y; Bar-Noy T; Brodeur MN; Salvador S; Lau S; Gotlieb W
Arch Gynecol Obstet; 2024 Jul; 310(1):587-593. PubMed ID: 38714562
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy response score as a predictor of survival in ovarian cancer patients.
Rodolakis I; Liontos M; Pergialiotis V; Haidopoulos D; Kaparelou M; Efthimios Vlachos D; Dimopoulos MA; Loutradis D; Rodolakis A; Bamias A; Thomakos N
Eur J Obstet Gynecol Reprod Biol; 2024 May; 296():233-238. PubMed ID: 38479209
[TBL] [Abstract][Full Text] [Related]
8. Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma.
Pölcher M; Braun M; Friedrichs N; Rudlowski C; Bercht E; Fimmers R; Sauerwald A; Keyver-Paik MD; Kübler K; Büttner R; Kuhn WC; Hernando JJ
Cancer Immunol Immunother; 2010 Jun; 59(6):909-19. PubMed ID: 20087581
[TBL] [Abstract][Full Text] [Related]
9. The Prognostic Value of PARP Expression in High-Grade Epithelial Ovarian Cancer.
Molnár S; Beke L; Méhes G; Póka R
Pathol Oncol Res; 2020 Oct; 26(4):2549-2555. PubMed ID: 32594311
[TBL] [Abstract][Full Text] [Related]
10. Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial.
Colomban O; Clamp A; Cook A; McNeish IA; You B
JCO Clin Cancer Inform; 2023 Apr; 7():e2200188. PubMed ID: 37075255
[TBL] [Abstract][Full Text] [Related]
11. Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care.
Norell CH; Butler J; Farrell R; Altman A; Bentley J; Cabasag CJ; Cohen PA; Fegan S; Fung-Kee-Fung M; Gourley C; Hacker NF; Hanna L; Høgdall CK; Kristensen G; Kwon J; McNally O; Nelson G; Nordin A; O'Donnell D; Schnack T; Sykes PH; Zotow E; Harrison S
Int J Gynecol Cancer; 2020 Nov; 30(11):1748-1756. PubMed ID: 32784203
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study).
Tavira B; Iscar T; Manso L; Santaballa A; Gil-Martin M; García García Y; Romeo M; Iglesias M; de Juan Ferré A; Barretina-Ginesta MP; Manzano A; Gaba L; Rubio MJ; de Andrea CE; González-Martín A
Clin Cancer Res; 2024 Jan; 30(1):176-186. PubMed ID: 37527007
[TBL] [Abstract][Full Text] [Related]
13. The Use of CA-125 KELIM to Identify Which Patients Can Achieve Complete Cytoreduction after Neoadjuvant Chemotherapy in High-Grade Serous Advanced Ovarian Cancer.
Zouzoulas D; Tsolakidis D; Tzitzis P; Sofianou I; Chatzistamatiou K; Theodoulidis V; Topalidou M; Timotheadou E; Grimbizis G
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610943
[TBL] [Abstract][Full Text] [Related]
14. Methodical Manipulation of the TME in Ovarian Cancer.
Soberanis Pina P; Oza AM
Clin Cancer Res; 2024 Jan; 30(1):12-16. PubMed ID: 37939000
[TBL] [Abstract][Full Text] [Related]
15. Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer.
Moffat GT; Kong W; MacKay HJ; McGee J; Booth CM; Ethier JL
Gynecol Oncol; 2024 Jan; 184():51-56. PubMed ID: 38281412
[TBL] [Abstract][Full Text] [Related]
16. Clinical factors predicting objective response to bevacizumab-based chemotherapies in advanced and recurrent epithelial ovarian cancer.
Khanmammadov N; Dogan I; Okay NS; Khishigsuren B; Azizy A; Saip P; Gasimli K; Aydiner A
Minerva Obstet Gynecol; 2024 Jun; ():. PubMed ID: 38837188
[TBL] [Abstract][Full Text] [Related]
17. Effect of bevacizumab in combination with chemotherapy for ovarian cancer on wound healing in patients: A meta-analysis.
Xue Y; Zhao F
Int Wound J; 2024 Apr; 21(4):e14531. PubMed ID: 38151891
[TBL] [Abstract][Full Text] [Related]
18. Effects of neoadjuvant chemotherapy for patients with obstructive colon cancer: A multicenter propensity score-matched analysis (YCOG2101).
Nakagawa K; Ishibe A; Ohya H; Ozawa M; Suwa Y; Watanabe J; Suwa H; Den K; Mori K; Momiyama M; Goto K; Endo I
Ann Gastroenterol Surg; 2024 Mar; 8(2):262-272. PubMed ID: 38455492
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Chemotherapy Is Effective in Those Infected With SARS-CoV-2: The Real-World Experience of a Large Chinese Breast Cancer Center.
Ma T; Ma T; Wang L; Wang H
J Breast Cancer; 2024 May; ():. PubMed ID: 38769687
[TBL] [Abstract][Full Text] [Related]
20. Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trial.
Chou HH; Chen WC; Yang LY; Huang HJ; Chang WY; Lin H; Wu RC; Chen MY; Qiu JT; Huang KG; Chao A; Chang TC; Lai CH
Eur J Obstet Gynecol Reprod Biol; 2021 Jul; 262():13-20. PubMed ID: 33984725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
